COVID-19 and Liver Damage
An outbreak of unknown pneumonia, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), was reported in China at the end of December 2019. On February 11, 2020, the World Health Organization officially named SARS-CoV-2 infection COVID-19 (Coronavirus Disease 2019). The most...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2020-05-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/1055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839572763986100224 |
|---|---|
| author | L. Yu. Ilchenko I. G. Nikitin I. G. Fedorov |
| author_facet | L. Yu. Ilchenko I. G. Nikitin I. G. Fedorov |
| author_sort | L. Yu. Ilchenko |
| collection | DOAJ |
| description | An outbreak of unknown pneumonia, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), was reported in China at the end of December 2019. On February 11, 2020, the World Health Organization officially named SARS-CoV-2 infection COVID-19 (Coronavirus Disease 2019). The most common clinical manifestation of COVID-19 is pneumonia. However, with the spread of the COVID-19 pandemic and analysis of clinical data, symptoms that are not characteristic of “atypical” pneumonia have been identified in patients. Neurological symptoms, skin and eye damage, etc., are described. The extrapulmonary presence of SARS-CoV-2 was also detected in cholangiocytes. Virus-induced effects, systemic inflammation (“cytokine storm”), hypoxia, hypovolemia, hypotension in shock, drug-induced hepatotoxicity, etc., are considered possible factors of liver damage. In 14-53 % of COVID-19 patients, changes in biochemical parameters, which usually do not require drug therapy, can be recorded. Acute hepatitis is very rare. However, special attention should be given to COVID-19 patients at risk: after liver transplantation; receiving immunosuppressants and antiviral drugs; and in cases of decompensated cirrhosis, acute-on-chronic liver failure, and hepatocellular carcinoma. Constant data sharing and open access to research data, new technologies, and up-to-date guidelines are required. |
| format | Article |
| id | doaj-art-2d40fadbc9b64c6aba08c62c1f6b45ec |
| institution | Matheson Library |
| issn | 2226-6704 2411-6564 |
| language | Russian |
| publishDate | 2020-05-01 |
| publisher | SINAPS LLC |
| record_format | Article |
| series | Архивъ внутренней медицины |
| spelling | doaj-art-2d40fadbc9b64c6aba08c62c1f6b45ec2025-08-04T14:09:47ZrusSINAPS LLCАрхивъ внутренней медицины2226-67042411-65642020-05-0110318819710.20514/2226-6704-2020-10-3-188-197790COVID-19 and Liver DamageL. Yu. Ilchenko0I. G. Nikitin1I. G. Fedorov2Federal State Autonomous Institution of Higher Education «Pirogov Russian National Research Medical University» of the Russian Ministry of Health; Federal State Budgetary Scientific Institution Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of SciencesFederal State Autonomous Institution of Higher Education «Pirogov Russian National Research Medical University» of the Russian Ministry of Health; Federal State Autonomous Institution «National Medical Research Center of Rehabilitation» of the Russian Ministry of HealthFederal State Autonomous Institution of Higher Education «Pirogov Russian National Research Medical University» of the Russian Ministry of Health; State Budgetary Healthcare Institution «Buyanov City Clinical Hospital» of the Moscow Healthcare DepartmentAn outbreak of unknown pneumonia, caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), was reported in China at the end of December 2019. On February 11, 2020, the World Health Organization officially named SARS-CoV-2 infection COVID-19 (Coronavirus Disease 2019). The most common clinical manifestation of COVID-19 is pneumonia. However, with the spread of the COVID-19 pandemic and analysis of clinical data, symptoms that are not characteristic of “atypical” pneumonia have been identified in patients. Neurological symptoms, skin and eye damage, etc., are described. The extrapulmonary presence of SARS-CoV-2 was also detected in cholangiocytes. Virus-induced effects, systemic inflammation (“cytokine storm”), hypoxia, hypovolemia, hypotension in shock, drug-induced hepatotoxicity, etc., are considered possible factors of liver damage. In 14-53 % of COVID-19 patients, changes in biochemical parameters, which usually do not require drug therapy, can be recorded. Acute hepatitis is very rare. However, special attention should be given to COVID-19 patients at risk: after liver transplantation; receiving immunosuppressants and antiviral drugs; and in cases of decompensated cirrhosis, acute-on-chronic liver failure, and hepatocellular carcinoma. Constant data sharing and open access to research data, new technologies, and up-to-date guidelines are required.https://www.medarhive.ru/jour/article/view/1055coronaviruses that cause respiratory syndromenovel coronavirus diseaseliver damage |
| spellingShingle | L. Yu. Ilchenko I. G. Nikitin I. G. Fedorov COVID-19 and Liver Damage Архивъ внутренней медицины coronaviruses that cause respiratory syndrome novel coronavirus disease liver damage |
| title | COVID-19 and Liver Damage |
| title_full | COVID-19 and Liver Damage |
| title_fullStr | COVID-19 and Liver Damage |
| title_full_unstemmed | COVID-19 and Liver Damage |
| title_short | COVID-19 and Liver Damage |
| title_sort | covid 19 and liver damage |
| topic | coronaviruses that cause respiratory syndrome novel coronavirus disease liver damage |
| url | https://www.medarhive.ru/jour/article/view/1055 |
| work_keys_str_mv | AT lyuilchenko covid19andliverdamage AT ignikitin covid19andliverdamage AT igfedorov covid19andliverdamage |